These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37610817)

  • 1. Durability and long-term outcomes of biologic therapies in psoriasis.
    Rusiñol L; Carmona-Rocha E; Puig L
    Expert Rev Clin Immunol; 2024; 20(1):71-82. PubMed ID: 37610817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics.
    Prignano F; Pescitelli L; Trovato E; DI Cesare A; Cuccia A; Mazzatenta C; Pellegrino M; Marsili F; Castelli A; Brandini L; Niccoli MC; Taviti F; Ricceri F; Panduri S; Buggiani G; Ghilardi A; Rubegni P; Romanelli M; Pimpinelli N
    Ital J Dermatol Venerol; 2022 Dec; 157(6):469-479. PubMed ID: 35785927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologics in pediatric psoriasis.
    Wang WM; Jin HZ
    J Dermatol; 2023 Apr; 50(4):415-421. PubMed ID: 36651087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological treatment for erythrodermic psoriasis.
    Dogra S; Mehta H
    Expert Opin Biol Ther; 2022 Dec; 22(12):1531-1543. PubMed ID: 36154361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).
    Marcombes C; Penso L; Weill A; Dray-Spira R; Zureik M; Sbidian E
    Br J Dermatol; 2023 Oct; 189(5):561-568. PubMed ID: 37479503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic treatment of psoriasis in oncologic patients.
    Rusiñol L; Camiña-Conforto G; Puig L
    Expert Opin Biol Ther; 2022 Dec; 22(12):1567-1578. PubMed ID: 36422998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL).
    Seneschal J; Lacour JP; Bewley A; Faurby M; Paul C; Pellacani G; De Simone C; Horne L; Sohrt A; Augustin M; Hammond E; Reich K
    J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2566-2573. PubMed ID: 32364296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe and acute complications of biologics in psoriasis.
    Oussedik E; Patel NU; Cash DR; Gupta AS; Feldman SR
    G Ital Dermatol Venereol; 2017 Dec; 152(6):586-596. PubMed ID: 28895664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-IL 23 biologics for the treatment of plaque psoriasis.
    Vu A; Ulschmid C; Gordon KB
    Expert Opin Biol Ther; 2022 Dec; 22(12):1489-1502. PubMed ID: 36243011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data.
    Ding L; Chen C; Yang Y; Zhang X
    Front Immunol; 2024; 15():1349636. PubMed ID: 38384460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Survival of Biological Therapies for Psoriasis Treatment in Germany and Associated Costs: A Retrospective Claims Database Analysis.
    Mahlich J; Alba A; Hadad LE; Leisten MK; Peitsch WK
    Adv Ther; 2019 Jul; 36(7):1684-1699. PubMed ID: 31102203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis.
    Ruda RC; Kelly KA; Feldman SR
    J Dermatolog Treat; 2023 Dec; 34(1):2140569. PubMed ID: 36305624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologics in the treatment of pustular psoriasis.
    Wang WM; Jin HZ
    Expert Opin Drug Saf; 2020 Aug; 19(8):969-980. PubMed ID: 32615817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologics in pediatric psoriasis - efficacy and safety.
    Dogra S; Mahajan R
    Expert Opin Drug Saf; 2018 Jan; 17(1):9-16. PubMed ID: 29022425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database.
    Pina Vegas L; Penso L; Claudepierre P; Sbidian E
    JAMA Dermatol; 2022 May; 158(5):513-522. PubMed ID: 35319735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evidence-based review of the mechanism of action, efficacy, and safety of biologic therapies in the treatment of psoriasis and psoriatic arthritis.
    Brezinski EA; Armstrong AW
    Curr Med Chem; 2015; 22(16):1930-42. PubMed ID: 25921645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic therapies for psoriasis: an evidence-based update.
    Sandoval LF; Pierce A; Feldman SR
    Am J Clin Dermatol; 2014 Jul; 15(3):165-80. PubMed ID: 24496885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between the efficacy of biologics and clinical plaque psoriasis subtypes in Japanese patients: A single-center pilot study.
    Ito K; Bayaraa B; Imafuku S
    J Dermatol; 2019 Dec; 46(12):1160-1165. PubMed ID: 31556161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brodalumab Seems to Recover Its Therapeutic Efficacy After a Relatively Short "Washout" Period with Anti-TNF Agents: A Successful Pattern for Double-switch Therapy.
    Tampouratzi E; Sfaelos K; Talaiporou K; Douvali Τ; Katsantonis J
    Acta Dermatovenerol Croat; 2023 Aug; 31(1):48-50. PubMed ID: 37843093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.